STOCK TITAN

Iridex - IRIX STOCK NEWS

Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.

Iridex Corporation (IRIX) delivers innovative laser-based medical systems for ophthalmology, specializing in noninvasive treatments for glaucoma and retinal diseases. This news hub provides investors and healthcare professionals with timely updates on product developments, financial performance, and clinical advancements.

Access authoritative information about IRIX's proprietary MicroPulse technology, regulatory milestones, and global market initiatives. Our curated collection features earnings announcements, partnership updates, and clinical study results – all essential for tracking the company's position in medical device innovation.

Discover updates across key categories including new product clearances, international distribution expansions, and peer-reviewed research findings. Content is regularly updated to reflect IRIX's progress in enhancing ophthalmic care through advanced laser systems and procedural tools.

Bookmark this page for streamlined access to verified Iridex developments. Combine strategic business insights with technical expertise through our comprehensive news repository – your primary source for monitoring this medical technology leader's trajectory.

Rhea-AI Summary
Iridex Corporation and Imperial College Healthcare NHS Trust have announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse Transscleral Laser Therapy (TLT). The study, titled 'MicroPulse Transscleral Laser Therapy: A Prospective UK Study,' aims to expand Iridex’s global clinical portfolio and promises significant insights and advancements in glaucoma laser therapy, potentially revolutionizing treatment approaches and enhancing patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Summary
Iridex Corporation (IRDX) proudly announces the US launch of its next-generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration. The lasers offer multiple treatment modes, including continuous-wave and Iridex’ patented MicroPulse® Technology, providing a wide range of clinical control options and features to optimize the treatment of retinal disorders and glaucoma. The announcement was made ahead of their official showcase at the Hawaiian Eye and Retina 2024 Meeting from January 13-19, 2024. David Bruce, President and CEO of Iridex Corporation, highlighted the company's 35-year heritage of providing advanced laser solutions to ophthalmologists worldwide and the significant impact of the new laser innovations on patient treatment. Dr. Sam Mansour, Medical Director of the Virginia Retina Center, praised the compact design, intuitive user interface, and treatment-session recordings of the new Iridex 577 nm Laser, emphasizing the product's potential to improve patient flow and therapeutic tracking. The new lasers also offer comprehensive treatment reports, configurable preset filters, enhanced user experience, and MicroPulse® Laser Applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
-
Rhea-AI Summary
Iridex Corporation (Nasdaq: IRIX) retains full patient access to MicroPulse® Transscleral Laser Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
Rhea-AI Summary
Iridex Corporation (IRIX) successfully advocated for the revision of Medicare Local Coverage Determinations for Cyclophotocoagulation, resulting in broader patient qualification. The correction aligns with the conclusions and recommendations of the 2001 paper by the American Academy of Ophthalmology, allowing for reimbursement of patients with refractory glaucoma. Iridex plans to appeal for further broadening of patient criteria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19%
Tags
none
-
Rhea-AI Summary
IRIDEX Corporation (IRIX) Reports Q3 2023 Financial Results and Business Update, Highlighting Revenue, Strategic Review, and Glaucoma Reimbursement Developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
-
Rhea-AI Summary
IRIDEX Corporation (NASDAQ: IRIX) announced plans to host its third quarter financial results conference call on November 14, 2023, and participate in the upcoming Stifel Healthcare Conference on November 15, 2023. The Company specializes in ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences earnings
Rhea-AI Summary
Iridex Corporation to release financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
conferences earnings
-
Rhea-AI Summary
Iridex Corporation is conducting a strategic review to unlock shareholder value, engaging Piper Sandler as financial advisor. The company has a strong market position in laser-based medical systems for ophthalmology, with recent regulatory approvals and clinical trials expected to drive growth. Sales revenue and product offerings are robust. No assurance of a transaction or timeline for completion of the strategic process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.7%
Tags
none
-
Rhea-AI Summary
Iridex Corporation (Nasdaq: IRIX) reported a 7% year-over-year decrease in total revenue for the second quarter of 2023, with a 5% increase in Cyclo G6 product family revenue and a 9% decrease in retina product revenue. The company's net loss for the quarter was $2.8 million, or $0.17 per share. Cash and cash equivalents totaled $9.8 million as of July 1, 2023. The company expects Cyclo G6 probe sales to grow by 1% to 5% over 2022, with a total revenue expectation of $55 million to $57 million for the full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.21%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Iridex

Nasdaq:IRIX

IRIX Rankings

IRIX Stock Data

16.97M
13.34M
20.67%
19.45%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW